Analysts' ratings for Regenxbio (NASDAQ:RGNX) over the last quarter vary from bullish to bearish, as provided by 9 analysts.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $38.22, a high estimate of $55.00, and a low estimate of $21.00. This current average has increased by 1.25% from the previous average price target of $37.75.

Deciphering Analyst Ratings: An In-Depth Analysis

In examining recent analyst actions, we gain insights into how financial experts perceive...